Closer to FREEDOM From Uncertainty ∗Original Investigation Published on 2023-05-012024-09-05 Journal: Journal of the American College of Cardiology [Category] update2024, [키워드] apixaban Coronavirus disease 2019 enoxaparin Prognosis severe acute respiratory syndrome coronavirus 2 [DOI] 10.1016/j.jacc.2023.03.407 PMC 바로가기 [Article Type] Original Investigation
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19Original Investigation Published on 2023-03-062024-09-05 Journal: Journal of the American College of Cardiology [Category] update2024, [키워드] apixaban Coronavirus disease 2019 enoxaparin Prognosis severe acute respiratory syndrome coronavirus 2 [DOI] 10.1016/j.jacc.2023.02.041 PMC 바로가기 [Article Type] Original Investigation
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasoneArticle Published on 2022-02-012023-07-06 Journal: Journal of Thrombosis and Thrombolysis [Category] COVID19(2023년), [키워드] Anticoagulants apixaban COVID-19 Dexamethasone Embolism rivaroxaban thrombosis [DOI] 10.1007/s11239-021-02561-w PMC 바로가기
Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro proteaseResearch Article Published on 2022-01-112022-10-28 Journal: PLoS ONE [Category] COVID-19, [키워드] addition Anticoagulant apixaban betrixaban binding binding affinity disease examined in silico inhibit SARS-CoV-2 inhibitor M pro MPro patients with COVID-19 protease rivaroxaban the SARS-CoV-2 therapeutic effect thermophoresis [DOI] 10.1371/journal.pone.0262482 PMC 바로가기 [Article Type] Research Article
National trends in prescription drug expenditures and projections for 20212021 년 처방약 소비 및 예측의 국가 동향Article Published on 2021-07-092022-08-31 Journal: American journal of health-system pharmacy : AJHP [Category] 치료제, [키워드] adalimumab Analysis apixaban approvals approved Cancer change clinics Combination conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic database decrease driven by drug drugs estimate Evolution expected Expenditure expenditures Factor focus followed by growth health system hospital hospitals identify increase Increases insulin insulin glargine IQVIA Local myriad National pandemic predict prescription drug prescription expenditures. Quantitative reduced the United State The United States United States utilization were assessed [DOI] 10.1093/ajhp/zxab160 PMC 바로가기 [Article Type] Article
Can’t Dissolve Me Now: A COVID-19 Provoked Venous Thromboembolism Breaks Through Apixaban: Case ReportCase Report Published on 2021-05-282022-10-31 Journal: Clinical Practice and Cases in Emergency Medicine [Category] COVID-19, [키워드] apixaban break Case report Coronavirus disease 2019 COVID-19 COVID-19 patients Deep venous thrombosis dosage Effects endotheliopathy Evidence extension hypercoagulability Prevent protocol report Research subsequent Treatment Venous Thromboembolism VTE worsening [DOI] 10.5811/cpcem.2021.3.50505 PMC 바로가기 [Article Type] Case Report
Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C오래된 약, 새로운 트릭? 활성화된 단백질 C로 코로나19를 치료하는 근거Article Published on 2021-04-012022-09-11 Journal: Medical Hypotheses [Category] 치료법, 치료제, [키워드] activated activated protein C adaptive Antiviral agents antiviral treatments apixaban approach Aspirin clinical trial Coagulation consequence convalescent plasma COVID-19 COVID-19 pandemic COVID-19 patients COVID-19 therapeutics COVID-19 therapeutics. current described dysregulated immune response evaluated followed by heparin heparins Hope Hypothesis identify immune immune response immunomodulator immunomodulators Infection Inflammatory mechanism monoclonal antibodies Protein protein C researcher steroid Steroids therapeutic interventions therapeutic target Therapies therapy treating COVID-19 patient Treatment [DOI] 10.1016/j.mehy.2021.110537 PMC 바로가기 [Article Type] Article
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-03-102022-09-10 Journal: Trials [Category] SARS, 임상, 치료기술, [키워드] 1:1 absence acutely ill hospitalized medical patients Admission age allergy allocation concealment allocation sequence Alpha America and protocol Anticoagulant anticoagulation antiplatelet antithrombotic therapy apixaban arterial bleeding bleeding risk Blinding block sizes blood cell Brazil can not Canada Care Chain Reaction changed choice clinical trial clinically clinician Coagulation Coagulopathy Committee complex Composite computer-generated contraindication control group Controlled COVID COVID-19 Critical Critical illness cryoprecipitate D-dimer D-dimer value Dabigatran dalteparin Date death defined dependent on detect determine diagnosis of SARS-CoV-2 diagnostic Diagnostic imaging discretion disorder dissemination dose dual edoxaban electrocardiogram element elevated emergency room enoxaparin Enrollment evaluated exclusion criteria expected experimental group fibrinogen fondaparinux frozen plasma Health Organization hemoglobin heparin heparin-induced thrombocytopenia High dose high risk hospital Hospital admission hospitalised Hospitalized hospitalized patient hospitalized patients ICU ICU admission include inclusion criteria indicated individual inflammatory biomarkers Informed consent INR intensive care intensive care unit Interactive Web Response System intermediate dose Invasive mechanical ventilation involved Ireland isothermal amplification judgement limit LMWH Local low molecular weight low molecular weight heparin Major major bleeding mechanical ventilation Non-invasive non-invasive positive pressure ventilation nucleic acid number objective occur Open-label open-label trial outcome oxygen oxygen saturation participant Patient patients Phase 3 plasma Platelet Platelet count Platelets polymerase chain polymerase chain reaction positive pressure positive pressure ventilation power Pregnancy pressure ventilation protocol random random allocation randomised randomised controlled trial randomization Randomized controlled trial Rapid recruited red blood cell renal replacement therapy replacement therapy response responsible reverse transcriptase Reverse transcriptase polymerase chain reaction risk risk difference rivaroxaban room air Sample size Saudi Arabia secondary Secondary outcomes Standard standard care status stratified study population Study protocol supplementary material symptomatic the patient the United State therapeutic anticoagulation therapeutic dose therapy thrombocytopenia Thromboembolism Thromboprophylaxis tinzaparin transcriptase transfusion treated Trial Trial registration two-sided ULN unfractionated heparin United Arab Emirates United States Venous Thromboembolism Ventilator-free days Version Warfarin website World Health Organization [DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
Successful Use of Aspirin, Apixaban, and Viscoelastography in a Patient with Severe COVID Disease and Allergy to Porcine ProductsOriginal Article Published on 2021-01-292022-10-31 Journal: Hospital Pharmacy [Category] COVID-19, [키워드] abnormality acute respiratory syndrome allergy Anticoagulants anticoagulation anticoagulation treatment apixaban Aspirin assays Coagulopathy common coronavirus Course COVID Critical care described discharged hospital include intubation Patient Platelet product Prophylaxis Respiratory failure Safe SARS-CoV-2 Support therapy Thromboprophylaxis Venous Thromboembolism [DOI] 10.1177/0018578721990898 PMC 바로가기 [Article Type] Original Article
Hemorrhagic herpes zoster with contralateral multidermatomal distribution associated with rivaroxaban: An unusual presentationCase Report Published on 2021-01-172024-09-04 Journal: JAAD Case Reports [Category] 대상포진, [키워드] Anticoagulant apixaban clopidogrel concomitant multidermatomal herpes zoster dermatome Factor Xa Inhibitors hemorrhagic herpes zoster herpes zoster bilateralis immunocompetent purpuric herpes zoster rivaroxaban [DOI] 10.1016/j.jdcr.2020.12.038 PMC 바로가기 [Article Type] Case Report